Hemogenyx Pharmaceuticals LLC
lymphodepleting chemotherapy(Hemogenyx Pharmaceuticals LLC)은 Non-Hodgkin Lymphoma 표적 치료제로, Clear Cell Carcinoma; Phase 1 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 43.8% (ClinicalTrials.gov NCT02445248). 차별점: first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro.
Non-Hodgkin Lymphoma
Clear Cell Carcinoma; Phase 1
Active
CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Mye
vedotin), monoclonal antibodies (including acim
lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro
CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia
cytokine release syndrome, and one had grade ≥3 immune effector cell-associated neurotoxicity syndrome
apoptosis, particularly in naïve and central memory CD8 + T cells, and simultaneously enhances regulatory T cells and tolero
biomarkers exist to predict toxicity risk, underscoring the need for further research
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Hemogenyx Pharmaceuticals LLC
lymphodepleting chemotherapy(Hemogenyx Pharmaceuticals LLC)은 Non-Hodgkin Lymphoma 표적 치료제로, Clear Cell Carcinoma; Phase 1 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 43.8% (ClinicalTrials.gov NCT02445248). 차별점: first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro.
Non-Hodgkin Lymphoma
Clear Cell Carcinoma; Phase 1
Active
CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Mye
vedotin), monoclonal antibodies (including acim
lentiviral vector encoding a humanized anti-B cell maturation antigen (BCMA) CAR, in adult
humanized anti-B cell maturation antigen (BCMA) CAR, in adults with relapsed or refractory multiple myeloma
first-in-class autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma with progression after anti-pro
CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia
cytokine release syndrome, and one had grade ≥3 immune effector cell-associated neurotoxicity syndrome
apoptosis, particularly in naïve and central memory CD8 + T cells, and simultaneously enhances regulatory T cells and tolero
biomarkers exist to predict toxicity risk, underscoring the need for further research
bypass ex vivo manufacturing and lymphodepletion, potentially simplifying and accelerating access to cellular therapy; prelimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.